Contracts › 75A50124C00047
75A50124C00047: Advance the Development of PAAG17G (Drug Product: MIIST305), a Once Daily, Orally Administered, Gut-Restricted Drug, to Reduce Mortality and Morbidity Arising From Acute Exposure to Ionizing Radiation, Specifically Gastrointestinal (GI) Injury (Gi-Ar
Awarded to Synedgen, Inc. by Office of Assistant Secretary for Preparedness and Response.
$18.8Mobligated
$121.5Mpotential value
30 September 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50124C00047 |
|---|---|
| Awardee | Synedgen, Inc. |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 30 September 2024 to 30 September 2026 |
| Potential end | 22 December 2031 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record